La cadena de opciones muestra datos clave de las opciones de acciones de Compass Pathways a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Compass Pathways..

Compass Pathways (NASDAQ:CMPS) Bolsa, Cadena de Opciones

COMPASS PATHWAYS PLC

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Press Releases

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

CMPS

Absci

Abivax

aTyr Pharma

Aura Biosciences

Benitec Biopharma

Celcuity

CytomX Therapeutics

Erasca

Humacyte

ITeos Therapeutics

Jade Biosciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Organogenesis Holdings

Oruka Therapeutics

Precigen

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sage Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vigil Neuroscience

Cantor Fitzgerald

HC Wainwright & Co.

Canaccord Genuity

Stifel

RBC Capital

Comments

Compass Pathways

Compass Pathways (CMPS) Opciones

Compass Pathways (NASDAQ:CMPS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL